Optimize Your Visibility

ZEISS presents our newest VersaXRM® 730 3D X-ray microscope.

MVA:s CEO: “Our investments should improve people´s everyday lives”

Involuntary infertility and diabetes are two of the areas on the agenda of the Medicon Valley Alliance.

Ingrid Lönnstedt: What does the p-value mean?

The smaller the better, and preferably smaller than 0.05. A p-value smaller than 5% means that the treatment effect is statistically significant at 5% significa...

Japanese pharma to buy US drugmaker for $2.4 bln

Japanese Ono Pharmaceutical buys the American cancer drug developer Deciphera Pharmaceuticals in one of the largest acquisitions in the industry so far this year.

The route to vaccines for everyone: “We did not just sit around and wait”

The pandemic was in full swing, and no one knew when or even if a vaccine would come. At that point, the Swedish Minister of Social Affairs called with a propos...

Amrop Malmö AB

Here are the pharmaceutical companies best prepared for AI

How well prepared are pharmaceutical companies in the field of artificial intelligence? That is what a new analysis has tried to evaluate.

The first vaccine derived from cowpox

The British rural doctor could not forget the words of the peasant girl. Could that really be true? A couple of decades later, on 14 May 1796, he performed the ...

Novo Nordisk sues compounding pharmacies in the US

Novo Nordisk is suing compounding pharmacies in Florida, USA, because the company claims to have found impurities in the active ingredient in the obesity drug Wegovy.

BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”

For the first time since its inception, AstraZeneca’s BioVentureHub can now recruit new companies, as some of its tenants have grown significantly and are leavi...

Göran Stiernstedt: “We are the world’s worst at continuity”

Failed investments in primary care, an unreasonable system with online doctors and a public failure at coordinating the healthcare IT system. Göran Stiernstedt ...

Uppgifter: Sanofi tar in bud på konsumenthälsodivision

Den franska läkemedelsjätten Sanofi ska enligt uppgifter ha bett om initiala bud för sin konsumenthälsoverksamhet, som är värderad till runt 20 miljarder dollar.

Study: Popular diabetes drug may be effective against liver disease

After its success in diabetes and weight loss, a new potential therapeutic area has been identified for Ozempic and other GLP1 analogues. A new study links the ...

Did you know that not every sphere is really a round sphere?

ZEISS Metrology Expert Tip.

HAB Nicolai Johannsen

Webinar: Clinical evaluation and clinical investigation of medical devices

Whether you are a small medtech company or a large one, this webinar is a must-attend for anyone curious about how clinical studies on medical devices are conducted.

Sweden is organising a large life science conference as part of the EU presidency

On 26-27 June, Sweden will host a European meeting on life science.

ZEISS Quality Innovation Summit video

An event full of experiences, talks, innovations, speeches, and state-of-the-art technology.

19 medicines in Sweden are under investigation in a major EMA inquiry

unless new evidence can be provided that they are up to standard.

Norway finds its path in life science

The life science sector in Norway is on the rise.

Marie Gårdmark: ”The situation is not satisfactory”

”The legislative tool-box is limited, but carrots in the form of longer exclusivity has already proven successful, this has for example increased registration of new products in rare diseases. But will it also ...

Level up your medical expertise

Learn from innovative industry speakers from leading MedTech companies at ZEISS Quality Innovation Days.

Webinar: How to Plan And Analyze a Real-World Evidence Study

This webinar is for drug developers who want to understand the basic ideas of analyzing an RWE study, as well as avoiding the most common pitfalls.

Björn Arvidsson: ”We need to change perspective”

If you say “life science” to a person on the street and ask them to explain what it is, you will probably get no good answer. The same question to your network ...